Virtual Library

Start Your Search

Paul Naish

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      202P - Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape (ID 447)

      12:30 - 13:00  |  Presenting Author(s): Paul Naish

      • Abstract
      • Slides


      A lung cancer patient may turn to the internet for information on their disease, or on terms that their doctor has used. Anecdotal evidence suggests that such information may be outdated or incomplete. This research analyses the information available on lung cancer, aiming to support the identification of areas for improvement to ensure patients can be well-informed.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Researchers in 11 countries entered 22 search terms related to lung cancer into Google. Websites that appeared on the first page of search results were analysed to identify the content they included, the owners of the websites that provided the information, and the intended purpose of the information. Websites were reviewed in detail to determine the depth of information provided and how helpful, factual and current it was.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      885 unique websites were mapped (982 total; 97 duplicates removed). Sources of information differed between countries, with news sources as the leading type of website (375[42%]), followed by healthcare providers (115[13%]), online health resources (104[12%]), professional organisations (104[12%]), pharmaceutical companies (95[11%]), patient groups (72[8%]) and Wikipedia (20[2%]). 65% [573] of sources provided information on differences between non-small cell and small cell lung cancer and 29% [254] explained staging. 35% [310] of information sources covered point mutations (e.g. EGFR, ALK) and 19% [164] noted the availability of testing for point mutations. 23% [202] of information sources mentioned IO biomarkers (e.g. PD-1, PD-L1) and 11% [94] cited potential testing options for these. Chemotherapy was the most common treatment mentioned (58%[514]), followed by radiation therapy (44%[393]), surgery (40%[358]), immuno-oncology therapies (38%[336]) and targeted therapies (33%[288]).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Online lung cancer information was not always up-to-date or easily accessible. Information on treatment options was often either too complex or too high-level and incomplete. Websites that provided more up-to-date information were often not search optimised, therefore more difficult to find. Results varied considerably between countries but gaps in information were identified across all countries and these should be addressed.

      b651e8a99c4375feb982b7c2cad376e9 Editorial acknowledgement

      Writing assistance provided by GCI Health.

      934ce5ff971f1ab29e840a35e3ca96e9 Legal entity responsible for the study


      213f68309caaa4ccc14d5f99789640ad Funding


      682889d0a1d3b50267a69346a750433d Disclosure

      P. Naish: Employee and shareholder: AstraZeneca. E. Purdy: Employee: GCI Health.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.